CASI Pharmaceuticals, Inc. (CASI) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2019)
CASI's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
CASI Revenue Analysis (2013–2024)
As of March 2, 2026, CASI Pharmaceuticals, Inc. (CASI) generated trailing twelve-month (TTM) revenue of $26.8 million, reflecting significant decline in growth of -60.5% year-over-year. The most recent quarter (Q3 2025) recorded $3.1 million in revenue, down 26.3% sequentially.
Looking at the longer-term picture, CASI's 5-year compound annual growth rate (CAGR) stands at +47.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $43.1 million in 2022.
Revenue diversification analysis shows CASI's business is primarily driven by E V O M E L A (100%). With over half of revenue concentrated in E V O M E L A, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY), CASI has underperformed the peer group in terms of revenue growth. Compare CASI vs UTHR →
Peer Comparison
Compare CASI's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CASICurrent | $27M | -60.5% | +47.2% | -138.8% | |
| UTHR | $3.2B | +10.6% | +16.5% | 46.9% | |
| ZLAB | $460M | +15.3% | +56.5% | -49.9% | |
| AMRN | $229M | -6.2% | -11.9% | -40.2% | |
| ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
| ADMA | $426M | +27.6% | +70.8% | 32.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $28.5M | -15.8% | $11.1M | 39.1% | $-39,621,000 | -138.8% |
| 2023 | $33.9M | -21.4% | $20.1M | 59.2% | $-25,080,000 | -74.0% |
| 2022 | $43.1M | +42.9% | $27.3M | 63.3% | $-26,491,000 | -61.5% |
| 2021 | $30.2M | +99.2% | $17.6M | 58.4% | $-41,516,000 | -137.6% |
| 2020 | $15.1M | +266.5% | $5.6M | 37.2% | $-52,781,000 | -348.6% |
| 2019 | $4.1M | - | $196K | 4.7% | $-39,991,000 | -968.1% |
| 2018 | $0 | - | $-1,670,934 | - | $-26,504,446 | - |
| 2017 | $0 | - | $-117,779 | - | $-10,751,320 | - |
| 2016 | $0 | -100.0% | $-66,451 | - | $9.4M | - |
| 2015 | $48K | +101.1% | $41K | 86.9% | $7.2M | 14990.8% |
See CASI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CASI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CASI vs AGIO
See how CASI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CASI's revenue growth accelerating or slowing?
CASI revenue declined -60.5% year-over-year, contrasting with the 5-year CAGR of +47.2%. TTM revenue fell to $27M. This reverses the prior growth trend.
What is CASI's long-term revenue growth rate?
CASI Pharmaceuticals, Inc.'s 5-year revenue CAGR of +47.2% reflects the variable expansion pattern. Current YoY growth of -60.5% is below this long-term average.
How is CASI's revenue distributed by segment?
CASI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.